STAT
@statnews
Reporting from the frontiers of health & medicine.
Sign up for any of our newsletters here:
Joined July 2015
4.7K Following 165.1K Followers
An AstraZeneca heart disease trial failure has put Alnylam under pressure. It's mounting a defense of its medicines.
